Cold Genesys looks to China for a $10M cash infusion

Immuno-oncology biotech Cold Genesys raised a $10 million B round, rallying a stable of Chinese financiers as it moves forward with a late-stage cancer therapy. WI Harper Group co-led the round with Ally Bridge Group, the Hong Kong-headquartered investor that put up $13.6 million for Cold Genesys' A round last year. The funds will support the biotech's ongoing development of CG0070, an oncolytic virus wired to kill tumors with a dual mechanism of action, first multiplying within the cell to disrupt growth pathways, and then expressing the gene GM-CSF to recruit the body's dendritic cells and T cells. The treatment is now in pivotal trials in bladder cancer with data expected in 2018. More

Suggested Articles

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.

Grid Therapeutics is planning to start trials of its lead cancer immunotherapy GT103 next year after raising $5 million in second-round financing.

The IPO comes as the Flagship startup prepares to test its lead inflammatory disease and anticancer microbial strains in humans.